Octarine (Octarine Bio IVS) is a synthetic biology company that aims to develop psilocybin and cannabinoid derivatives. The company currently has $1.8 million in funding but hasn’t made (commercial) products.


“Using our unique biosynthetic platform we engineer microorganisms to produce a range of natural and novel cannabinoid and psilocybin derived molecules with improved pharmacokinetic and therapeutic properties.”


At the start of 2020, the company announced that they received (seed) funding from Oskare Capital and Bruce Linton (former CEO of Canopy Growth Cooperation). Previously they were part of the BioInnovation Institute’s Business Acceleration Academy-program (BAA-program).

In November they added money from the Danish State Growth Fund to this seed funding, totalling the funding at $1.8 million.

Key Staff

  • Nethaji Gallage, CEO & Co-founder
  • Nick Milne, CSO & Co-founder
  • Maria Jesus
  • Victor Forman


Nick Milne previously worked as a postdoc at DTU Biosustain (The Novo Nordisk Foundation Center for Biosustainability) and Octarine was spun out from here.


Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account